10-Q: Papa Medical Reports Strong Q2 Growth Amid Cash Burn

Papa Medical Inc. announced significant revenue and net income growth for the six months ended June 30, 2025, driven by E-vapor sales and new products, despite a notable decrease in cash reserves.

Summary

• Total revenues increased by 88.2% to US$32.6 million for the six months ended June 30, 2025, compared to US$17.3 million in the prior year.
• Net income surged by 89.6% to US$1.41 million for the six months ended June 30, 2025, up from US$0.74 million in the same period of 2024.
• Gross profit grew by 76.5% to US$7.6 million, although the gross profit margin slightly decreased from 25.0% to 23.4% for the six-month period, attributed to volume-related cost increases and product mix adjustments.
• Operating expenses increased by 74.7% to US$5.7 million, with research and development expenses rising by 98.5% and selling and marketing expenses by 75.3%.
• Cash and cash equivalents decreased significantly to US$1.18 million as of June 30, 2025, from US$4.75 million at December 31, 2024.
• Net cash used in operating activities increased to US$3.26 million for the six months ended June 30, 2025, from US$1.58 million in the prior year, primarily due to increased inventories and reduced advances from customers.
• The company continues preparations for its initial public offering (IPO) in the United States, with US$1.12 million in deferred offering costs as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue and net income growth, driven by increased demand and product development. However, a significant decrease in cash and increased cash outflow from operations, coupled with high customer and supplier concentration, present notable liquidity and operational risks. The ongoing IPO process and potential future capital raises indicate a need for external funding for growth.

Positives

• Total revenues increased by 88.2% to US$32.6 million for the six months ended June 30, 2025, demonstrating strong market demand.
• Net income grew by 89.6% to US$1.41 million for the six months ended June 30, 2025, reflecting improved profitability.
• Operating income surged by 82.2% to US$1.9 million, indicating efficient management of growing operations.
• Expansion of the customer base, with 19 new clients added in the first half of 2025, contributed to increased sales volume and improved brand recognition.
• Increased investment in Research and Development (98.5% increase) for new E-vapors series, 'iPrefer', and upgrading existing products, signals innovation and future growth potential.
• Sales of newly developed medical nebulizers and online candy sales contributed to revenue growth, diversifying product offerings.

Negatives

• Cash and cash equivalents decreased substantially by 75.2% to US$1.18 million as of June 30, 2025, from US$4.75 million at December 31, 2024.
• Net cash used in operating activities increased to US$3.26 million for the six months ended June 30, 2025, from US$1.58 million in the prior year, indicating higher cash burn.
• Gross profit margin slightly decreased to 23.4% for the six months ended June 30, 2025, from 25.0% in the prior year, due to volume-related cost increases and product mix adjustments.
• High concentration of customers, with two customers accounting for 68.4% of total revenues for the six months ended June 30, 2025, and one customer representing 64.4% of accounts receivable.
• Significant reliance on a few major suppliers, with three third-party suppliers accounting for approximately 83.3% of total accounts payable as of June 30, 2025.
• Extensive related party transactions, including significant payables and service expenses with Shenzhen Feellife, an affiliate controlled by the principal shareholder, which could pose governance risks.

Risks

• The effect of legislation and regulations affecting the Hemp and consuming E-vapors industry could materially impact business operations and profitability.
• The international market for E-vapors is presently primarily limited to certain states in the United States, restricting global expansion opportunities.
• Ability to obtain regulatory approval to market additional Hemp and consuming E-vapors in the United States, Europe, and other target countries and regions is crucial for growth.
• The company's ability to develop and market Hemp and consuming E-vapors to meet the changing tastes of users is essential for sustained demand.
• Concentration of credit risk exists with US$397,791 of cash and cash equivalents held by financial institutions being uninsured as of June 30, 2025.
• High customer concentration, with two customers accounting for 68.4% of total revenues for the six months ended June 30, 2025, poses a significant business risk.
• High supplier concentration, with three third-party suppliers accounting for approximately 83.3% of total accounts payable, could lead to supply chain vulnerabilities.
• Potential for future impairment losses on long-lived assets if significant adverse changes occur, such as intensified market competition or technology obsolescence.
• Costs of operating as a public company are expected to increase after the IPO, including additional legal, accounting, corporate governance, and investor relations expenses.

Future Outlook

Management expects selling and marketing expenses to continue increasing in absolute dollars as the company expands its sales force and grows its presence. Additional expenses are anticipated after the completion of the IPO due to the costs associated with operating as a public company, including legal, accounting, corporate governance, and investor relations. Research and development expenses are expected to vary as a percentage of revenue. The company believes its existing cash balances, cash flows from operations, and access to capital markets will be sufficient to meet working capital requirements for at least the next twelve months and does not anticipate needing additional financing for liquidity within this period. However, to execute growth strategies and scale production capacity, additional equity financing may be necessary. The company may seek to issue equity or debt securities or obtain credit facilities if cash requirements exceed current holdings and intends to fund future capital expenditures with existing cash, bank loans, and IPO proceeds. The balance of contract liabilities as of June 30, 2025, is expected to be recognized as revenue within the next three months.

Management Comments

• Our gross profit surged by 68.7% to US$3.6 million, compared to US$2.1 million for the three months ended June 30, 2024, primarily driven by expanded sales volumes.
• Our gross profit margin slightly decreased to 24.8% for the three months ended June 30, 2025, from 24.9% for the same period in 2024, primarily due to adjustments in product mix to meet evolving customer preferences.
• The 82.2% operating profit surge was primarily due to the significant increase in gross profit, which grew at a faster rate than our operating expenses.
• We expect our selling and marketing expenses to continue to increase in absolute dollars as we expand our sales force and continue to grow our presence.
• We expect to incur additional expenses after we complete this offering, primarily due to the costs of operating as a public company.
• We believe that our existing cash balances, cash flows expected to be generated from operations, and access to capital markets will be sufficient to meet our working capital requirements for at least the next twelve months.
• We do not anticipate requiring additional financing to meet our liquidity needs within the next twelve months.
• To execute our growth strategies, we plan to expand our business operations, which may necessitate additional equity financing to scale production capacity and address market demand.

Industry Context

Papa Medical Inc. operates in the Hemp cannabinoid E-vapors industry, which is characterized by evolving legislation and regulations. The company's primary market is currently limited to certain states in the United States, indicating a potentially restricted international market for E-vapors. The company's focus on research and development, including new E-vapors series like 'iPrefer' and medical nebulizers, aligns with broader industry trends of product innovation and diversification to meet changing consumer preferences and expand into related health sectors.

Corporate Governance

Legal Proceedings

• Not a party to any material legal or administrative proceedings as of June 30, 2025.
• May be involved in legal proceedings or subject to claims incident to the ordinary course of business, with outcomes inherently uncertain and potential for adverse impact due to defense/settlement costs or diversion of resources.

Related Party Transactions

• Amounts due to Shenzhen Feellife (an affiliate directly controlled by the principal shareholder) totaled US$3,254,064 as of June 30, 2025, including payables for purchases of Hemp cannabinoid E-vapors, packaging materials, and mould equipment.
• The Group transferred net amounts due from twelve other related parties (FGP, Cpresso, Vplus, Shenzhen LFS, Feel Life, Hooloo, FL MEDICAL, FL GLOBE, Joincare, IOTA, FEELLIFE HOLDING, and Shenzhen Huacheng) totaling US$766,941 for the six months ended June 30, 2025, to Shenzhen Feellife based on a Debit Waiver Agreement dated April 1, 2024.
• PAPA Health entered into a four-year business process outsourcing service agreement with Shenzhen Feellife on January 1, 2022, for services including product technology R&D, marketing, and production management, with service expenses calculated based on actual labor costs.
• Purchases from Shenzhen Feellife amounted to US$1,323,960 for the six months ended June 30, 2025.
• Service expenses paid to Shenzhen Feellife were US$1,368,768 for the six months ended June 30, 2025.
• Rental expenses paid to Cpresso, LLC (controlled by Shenzhen LFS) were US$226,500 for the six months ended June 30, 2025.
• Shenzhen Feellife individually represented 1.4% of total cost of revenues, 26.6% of total selling and marketing expenses, 6.8% of total general and administrative expenses, and 31.2% of total research and development expenses for the six months ended June 30, 2025.
• Amounts due to Ms. Hua Yao (Chief Financial Officer) were US$105 as of June 30, 2025, representing reimbursements for office expenses.

Stakeholder Impact

• Shareholders: Strong revenue and net income growth are positive, but significant cash burn and potential future equity dilution from capital raises could be concerns. High related-party transaction volume may also raise governance questions.
• Employees: Increased R&D personnel and expansion of the sales force suggest job growth and opportunities within the company.
• Customers: Increased demand for products, new product development (e.g., iPrefer E-vapors, medical nebulizers), and improved brand recognition indicate a positive impact on customer satisfaction and product availability.
• Suppliers: High concentration with a few key suppliers, including related parties, could create dependencies and potential risks if relationships change or supply is disrupted.
• Creditors: The substantial decrease in cash and increased cash used in operating activities might be a concern, although management asserts sufficient liquidity for the next twelve months. Future debt financing could increase leverage.

Next Steps

• Expand sales force and grow presence.
• Continue to develop and market Hemp and consuming E-vapors to meet changing tastes.
• Obtain regulatory approval to market additional products in the United States, Europe, and other target countries.
• Complete the initial public offering (IPO) in the United States.
• Expand business operations, potentially through additional equity financing.
• Fund future capital expenditures with existing cash, bank loans, and IPO proceeds.
• Recognize remaining contract liabilities as revenue within the next 3 months (from June 30, 2025).

Key Dates

Recommendation

While Papa Medical Inc. demonstrates impressive revenue and net income growth, driven by strong demand for its E-vapors and new product introductions, several factors warrant a 'Hold' recommendation. The significant decrease in cash and increased cash outflow from operations raise liquidity concerns, despite management's assertion of sufficient funds for the next 12 months. High customer and supplier concentration, along with extensive related-party transactions, introduce notable operational and governance risks. The ongoing IPO and plans for future capital raises suggest a need for external funding to sustain growth, which could lead to shareholder dilution. Investors should monitor the company's cash management, diversification efforts, and the successful execution of its IPO and expansion strategies before considering a stronger position.

Keywords

Hemp cannabinoid E-vapors, consuming E-vapors, medical nebulizers, online candy sales, quarterly report, financial performance, revenue growth, net income, operating expenses, related party transactions, IPO, liquidity, capital resources, market risk, regulatory approval, product development, SEC filing